Galapagos N.V. (GLPG) - Total Liabilities
Based on the latest financial reports, Galapagos N.V. (GLPG) has total liabilities worth €1.25 Billion EUR (≈ $1.46 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore GLPG cash flow conversion to assess how effectively this company generates cash.
Galapagos N.V. - Total Liabilities Trend (2004–2024)
This chart illustrates how Galapagos N.V.'s total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Galapagos N.V. to evaluate the company's liquid asset resilience ratio.
Galapagos N.V. Competitors by Total Liabilities
The table below lists competitors of Galapagos N.V. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Calibre Mining Corp
TO:CXB
|
Canada | CA$880.29 Million |
|
Suzhou Victory Precision Manufacture Co Ltd
SHE:002426
|
China | CN¥4.18 Billion |
|
NFI Group Inc
TO:NFI
|
Canada | CA$2.61 Billion |
|
Zhengzhou GL Tech Co Ltd
SHE:300480
|
China | CN¥641.74 Million |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥2.76 Billion |
|
Sanquan Food Co Ltd
SHE:002216
|
China | CN¥3.04 Billion |
|
Hunan Corun New Energy Co Ltd
SHG:600478
|
China | CN¥7.30 Billion |
|
Hugel Inc
KQ:145020
|
Korea | ₩96.68 Billion |
Liability Composition Analysis (2004–2024)
This chart breaks down Galapagos N.V.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Galapagos N.V. worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Galapagos N.V.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Galapagos N.V. (2004–2024)
The table below shows the annual total liabilities of Galapagos N.V. from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €1.24 Billion ≈ $1.45 Billion |
-20.68% |
| 2023-12-31 | €1.56 Billion ≈ $1.83 Billion |
-29.28% |
| 2022-12-31 | €2.21 Billion ≈ $2.58 Billion |
-13.39% |
| 2021-12-31 | €2.55 Billion ≈ $2.98 Billion |
-16.33% |
| 2020-12-31 | €3.05 Billion ≈ $3.56 Billion |
-4.56% |
| 2019-12-31 | €3.19 Billion ≈ $3.73 Billion |
+1317.53% |
| 2018-12-31 | €225.25 Million ≈ $263.34 Million |
-17.88% |
| 2017-12-31 | €274.29 Million ≈ $320.68 Million |
-15.51% |
| 2016-12-31 | €324.64 Million ≈ $379.53 Million |
+318.81% |
| 2015-12-31 | €77.52 Million ≈ $90.62 Million |
+20.49% |
| 2014-12-31 | €64.33 Million ≈ $75.21 Million |
-46.50% |
| 2013-12-31 | €120.24 Million ≈ $140.57 Million |
+2.87% |
| 2012-12-31 | €116.88 Million ≈ $136.65 Million |
+173.86% |
| 2011-12-31 | €42.68 Million ≈ $49.90 Million |
-6.11% |
| 2010-12-31 | €45.45 Million ≈ $53.14 Million |
+30.49% |
| 2009-12-31 | €34.83 Million ≈ $40.72 Million |
+0.96% |
| 2008-12-31 | €34.50 Million ≈ $40.33 Million |
-31.13% |
| 2007-12-31 | €50.10 Million ≈ $58.57 Million |
-13.78% |
| 2006-12-31 | €58.10 Million ≈ $67.93 Million |
+184.45% |
| 2005-12-31 | €20.43 Million ≈ $23.88 Million |
+289.38% |
| 2004-12-31 | €5.25 Million ≈ $6.13 Million |
-- |
About Galapagos N.V.
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product c… Read more